-
Je něco špatně v tomto záznamu ?
Protizánětlivé léky a ateroskleróza
[Anti-inflammatory drugs and atherosclerosis]
Sami P. Moubayed, Therese M. Heinonen, Jean-Claude Tardif
Jazyk čeština Země Česko
- MeSH
- antiflogistika nesteroidní terapeutické užití MeSH
- ateroskleróza farmakoterapie komplikace metabolismus MeSH
- kardiovaskulární látky terapeutické užití MeSH
- lidé MeSH
- lipoproteiny metabolismus MeSH
- monocyty metabolismus MeSH
- zánět farmakoterapie komplikace metabolismus MeSH
- Check Tag
- lidé MeSH
Inflammation contributes to the formation and progression of atherosclerosis and the therapeutic potential of some anti-inflammatory drugs has been evaluated for possible antiatherosclerotic effects. This review will briefly describe the mechanisms underlying the inflammation-atherosclerosis connection, the effect of various anti-inflammatory therapies on atherosclerotic disease and a sampling of the potential targets and agents under evaluation. RECENT FINDINGS: Some agents with anti-inflammatory properties appear to have beneficial effects on atherosclerosis or subsequent risk for cardiovascular events, while others have been disappointing. The anti-inflammatory actions of statins have been linked retrospectively with their favorable effects on atherosclerosis progression and clinical outcomes. The cardiovascular safety of COX-2 inhibitors is being assessed prospectively in patients with atherosclerosis. Potential new therapeutic agents targeting other inflammatory mechanisms and oxidative stress are being evaluated in animal models and clinical trials. SUMMARY: Due to the contributory inflammatory pathways in atherosclerosis, the properties of existing and novel anti-inflammatory agents are being carefully and actively evaluated in cardiovascular disease. Advances in our understanding of both atherosclerosis and the inflammatory contributors may play an important role in future strategies to decrease the incidence of atherosclerotic cardiovascular disease.
Anti-inflammatory drugs and atherosclerosis
Lit.: 65
- 000
- 00000naa 2200000 a 4500
- 001
- bmc07513971
- 003
- CZ-PrNML
- 005
- 20111210124757.0
- 008
- 081215s2008 xr e cze||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a cze $b eng
- 044 __
- $a xr
- 100 1_
- $a Moubayed, Sami P.
- 245 10
- $a Protizánětlivé léky a ateroskleróza / $c Sami P. Moubayed, Therese M. Heinonen, Jean-Claude Tardif
- 246 11
- $a Anti-inflammatory drugs and atherosclerosis
- 314 __
- $a Department of Medicine, Montreal Heart Institute and Université de Montréal, Montreal
- 504 __
- $a Lit.: 65
- 520 9_
- $a Inflammation contributes to the formation and progression of atherosclerosis and the therapeutic potential of some anti-inflammatory drugs has been evaluated for possible antiatherosclerotic effects. This review will briefly describe the mechanisms underlying the inflammation-atherosclerosis connection, the effect of various anti-inflammatory therapies on atherosclerotic disease and a sampling of the potential targets and agents under evaluation. RECENT FINDINGS: Some agents with anti-inflammatory properties appear to have beneficial effects on atherosclerosis or subsequent risk for cardiovascular events, while others have been disappointing. The anti-inflammatory actions of statins have been linked retrospectively with their favorable effects on atherosclerosis progression and clinical outcomes. The cardiovascular safety of COX-2 inhibitors is being assessed prospectively in patients with atherosclerosis. Potential new therapeutic agents targeting other inflammatory mechanisms and oxidative stress are being evaluated in animal models and clinical trials. SUMMARY: Due to the contributory inflammatory pathways in atherosclerosis, the properties of existing and novel anti-inflammatory agents are being carefully and actively evaluated in cardiovascular disease. Advances in our understanding of both atherosclerosis and the inflammatory contributors may play an important role in future strategies to decrease the incidence of atherosclerotic cardiovascular disease.
- 650 _2
- $a antiflogistika nesteroidní $x terapeutické užití $7 D000894
- 650 _2
- $a ateroskleróza $x farmakoterapie $x komplikace $x metabolismus $7 D050197
- 650 _2
- $a kardiovaskulární látky $x terapeutické užití $7 D002317
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a zánět $x farmakoterapie $x komplikace $x metabolismus $7 D007249
- 650 _2
- $a lipoproteiny $x metabolismus $7 D008074
- 650 _2
- $a monocyty $x metabolismus $7 D009000
- 700 1_
- $a Heinonen, Therese M.
- 700 1_
- $a Tardif, Jean-Claude
- 773 0_
- $w MED00156015 $t Current opinion in lipidology $g Roč. 2, č. 2 (2008), s. 25-31 $x 1802-372X
- 910 __
- $a ABA008 $b B 2483 $c 129 $y 1
- 990 __
- $a 20081215124735 $b ABA008
- 991 __
- $a 20081215153307 $b ABA008
- 999 __
- $a ok $b bmc $g 629566 $s 482021
- BAS __
- $a 3
- BMC __
- $a 2008 $b 2 $c 2 $d 25-31 $i 1802-372X $m Current Opinion in Lipidology $x MED00156015
- LZP __
- $a 2008-23/mkme